The roles of Wnt/β-catenin signaling pathway related IncRNAs in cancer

Xiao-Yi Hu1,2,4*, Ping-Fu Hou1,2*, Teng-Teng Li5*, Hao-Yu Quan1,2, Min-Le Li1,2, Tian Lin1,2, Jin-Jin Liu1,2, Jin Bai1,2,5*, Jun-Nian Zheng1,2,3*

1. Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China;
2. Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China;
3. Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China;
4. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China;
5. Department of Gastrointestinal Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.

* These authors contributed equally to this work.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.06.19; Accepted: 2018.10.07; Published: 2018.11.02

Abstract

Long noncoding RNAs (lncRNAs), with length of more than 200 nucleotides, are not translated into proteins but involved in multiple diverse diseases, especially tumorigenesis. The dysregulation of lncRNAs greatly contributes to the progression of various tumors through specific signaling pathways, including Wnt/β-catenin signaling pathway, which is associated with malignant features of tumors. The interactions between lncRNAs, which have specific expression characteristics in diverse cancer tissues, and Wnt/β-catenin signaling pathway, exhibit potential as novel biomarkers and therapeutic targets. In this review, we aim to present research findings on the roles of Wnt pathway-related lncRNAs and their effects on Wnt/β-catenin signaling to regulate tumorigenesis in different cancer types. Results may be used as basis to develop or improve strategies for treatment of different carcinomas.

Key words: cancer, long non-coding RNA, Wnt/β-catenin signaling pathway

Role of lncRNAs in cancers

Long noncoding RNAs (lncRNAs), a class of nonprotein coding transcripts, have a length of more than 200 nucleotides[1] and participate in chromatin remodeling, transcriptional control, posttranscriptional processing, and protein metabolism[2-4]. Scholars have focused on lncRNAs since lncRNA H19 was reported in 1990[5]. Many lncRNAs participate in the pathogenesis of different diseases[6]; such lncRNAs include H19[7] in abdominal aortic aneurysm (AAA), ROR in myocardial I/R injury[8], and DANCR in osteoarthritis[9]. With the development of bioinformatics and functional genomics, studies have found that lncRNAs exhibit significant functions in tumorigenic processes, such as cell proliferation, apoptosis, differentiation, and invasion.

Once considered as a crucial component of tumorigenesis, lncRNAs have been discovered to be associated with different cancers. For instance, MALAT-1 promotes the migration, invasion, and epithelial–mesenchymal transition (EMT) of gastric cancer (GC) cells[10]. High expression levels of HOTAIR[11] and CCAL[12] are correlated with poor prognosis in patients with CRC. Overexpression of HOTAIR is highly linked with the progression and metastasis of early-stage, surgically resected breast cancer[13]. The dysregulation of lncRNAs is associated with tumorigenesis, and their aberrant expression has important pathogenic consequences through different mechanisms. Guide lncRNAs bind
to the regulatory or enzymatically active protein complexes and guide them to specific target gene promoters or genomic loci[14]. Scaffold lncRNAs provide central platforms for various protein complexes to tether to so they can be guided to specific location[14]. Decoy lncRNAs activate or silence genes by interacting with transcription factors or repressors to bind to the target gene promoters[15]. Moreover, lncRNAs considerably affect specific signaling pathways because they regulate cancer cell survival and death; the expression of lncRNAs indicates an active signaling event regardless of their roles in the signaling process[15]. For example, Sun et al. found that the downregulation of lncRNA RP11-708H21.4 promoted colorectal cancer (CRC) tumorigenesis through the AKT/mTOR pathway[16]. Meanwhile, metaLnc9 could activate the AKT/mTOR pathway to facilitate the metastasis of nonsmall cell lung cancer (NSCLC)[17].

Increasing lines of evidence have confirmed that lncRNAs are involved in various cellular processes and appear to be tissue-specific drivers of cancer phenotypes. Hence, lncRNAs could be used as predictors of patient prognosis and as treatment targets[18].

**Wnt Signaling Pathway**

The Wnt signaling pathway is an important extracellular pathway that was discovered in 1982 along with proto-oncogene Int1 (also known as Wnt1)[19]. This complex and ancient pathway is involved in a multitude of developmental processes, such as cell growth, differentiation, individual development, migration, genetic stability, apoptosis, self-renewal of stem cells, and maintenance of adult tissue homeostasis[20, 21].

The Wnt signaling pathway comprises two different intracellular signaling pathways: the β-catenin-dependent pathway (known as the canonical Wnt pathway) and the β-catenin-independent pathway (known as the noncanonical Wnt pathway). Compared with other signaling pathways, the canonical Wnt/β-catenin pathway is highly evolutionary conserved and mainly involves β-catenin. In the absence of Wnt ligands, cytoplasmic β-catenin is recruited into a destruction complex containing glycogen synthase kinase 3β, adenomatous polyposis coli (APC), casein kinase (CK) 1α, and axin and is then phosphorylated by CK1α and GSK3β. The phosphorylated β-catenin is directly ubiquitinated by β-transducin repeat-containing protein E3 ligase and degraded by the 26S proteasome pathway[22] to maintain a low level of β-catenin. When the Wnt ligand binds to the frizzled receptors and coreceptor lipoprotein-related protein (LRP), the former activates dishevelled proteins to phosphorylate low-density lipoprotein receptor-related proteins 5/6 (LRP5/6), which in turn disassembles the destruction complex so the phosphorylated LRP5/6 provides a binding site for GSK3β and axin. The stabilized β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it binds to the T-cell factor/lymphocyte enhancer factor (TCF/LEF) of the transcriptional complex to activate the transcription of downstream genes, such as c-Myc, cyclin D1, matrix metalloproteinase 1 (MMP-1), and MMP-7[23].

The noncanonical Wnt pathway is further divided into the Wnt/Ca2+ pathway and the Wnt/planar cell polarity (PCP) pathway. As a core mediator, the Wnt ligand is needed in both pathways to bind to frizzled receptors and LRP and subsequently activate the DSH protein[24]. Hence, Wnt proteins depend on a particular combination of Wnt receptors and coreceptors. The interaction of different Wnt ligands, which are all Cys-rich encoded by 19 Wnt genes, with different Fzd receptors would decide the downstream signaling pathway.

WNT signaling can promote or inhibit tumor initiation, growth, and metastasis and drug resistance in a cancer stage-specific or a cancer type-specific manner[25] by regulating the expression of specific target genes, such as c-myc, E-cadherin, and cyclin D1. The high expression of constitutively active β-catenin promotes the growth of myeloma cells in vitro[26]. A previous work reported a high level of nuclear β-catenin in subpopulations of leukemia stem cells that can form tumors with short latency in mice[27]. Moreover, overexpressing WNT1 induces the invasiveness of MCF7 breast cancer cells, and this effect can be attenuated by blocking β-catenin-dependent transcription[28]. Hence, identifying genetic factors and biomarkers is important for predicting responses to treatment with WNT pathway modulators, for diagnosis and determining the prognosis of the cancer, and for developing novel therapeutics.

**Wnt pathway-related lncRNAs and colorectal cancer (CRC)**

LncRNAs with differential expression profiles in clinical CRC tissues have been suggested to contribute to the activation or inactivation of the Wnt pathway to regulate tumorigenesis. To explore the different roles of lncRNAs in the progression of CRC via the Wnt pathway, we enumerate all of the reported Wnt pathway-related lncRNAs (Table 1).
Tumor promoting role of Wnt pathway-modulating lncRNAs in CRC

With the development of scientific technology, increasing lines of evidence show that lncRNA–miRNA interactions mediate the functions of lncRNAs in CRC. Many CRC-related lncRNAs bind to miRNAs instead of the target mRNAs to regulate the expression of target genes[29]; some of which activate the Wnt signaling pathway and promote tumorigenesis. For example, Zhigang Xiao et al. reported[30] that lncRNA HOTAIR enhances drug resistance and promotes the proliferation of CRC cells through the miR-203a-3p-mediated Wnt/β-catenin signaling pathway. LncRNA MIR100HG confers cetuximab resistance in CRC[31] because its two embedded miRNAs (miR-100 and miR-125b) downregulate the five negative regulators (DKK1[32], DKK3[33], ZNRF3[34], RNF43[35], and APC2) of canonical Wnt/β-catenin signaling[36, 37]. Furthermore, XIST is highly conserved to bind to miR-34a[38]. Given that miR-34a is closely linked with the 3′-UTR of WNT1, the production of WNT1 mRNA and its corresponding protein cannot be decreased in CRC due to the strong binding between XIST and miR-34a. In the presence of the WNT1 ligand, β-catenin can translocate to the nucleus to express growth- and invasion-associated genes.

Several lncRNAs, such as CASC11[39], CCAL[12], and TCF7[40], could be involved in promoting the proliferation and invasion of CRC through diverse mechanisms via the Wnt/β-catenin pathway. CASC11[39] enhances the stability of hnRNP-K to increase its expression levels as a cytoplasmic lncRNA. By interacting with AXIN and GSK3 and forming a complex with β-catenin, hnRNP-K protects β-catenin from degradation and promotes its nuclear accumulation to activate the downstream of Wnt signaling. The ability of CCAL to enhance proliferation, cell cycle progression, invasion, and migration could be partly attributed to the fact that it inhibits AP-2α and subsequently activates the Wnt/β-catenin signaling pathway[12]. In addition, TCF7 expression is regulated by lncTCF7 to activate WNT signaling and thus promote tumor metastasis and invasion in CRC[40].

Tumor suppressor role of Wnt pathway-modulating lncRNAs in CRC

In contrast to many oncogenic lncRNAs, lncRNAs can alter the expression and activity of essential Wnt/β-catenin modulators to deregulate Wnt/β-catenin signaling in CRC. For example, lncRNA BC032913 upregulates the expression of TIMP3 and inhibits the nuclear translocation of β-catenin, thereby inactivating the Wnt/β-catenin pathway to suppress CRC metastasis[41]. LincRNA-p21 can directly deregulate β-catenin at the posttranscriptional level to suppress the Wnt/β-catenin signaling pathway and enhance the radiosensitivity of CRC radiotherapy[42]. Although the oncogenic interactions between lncRNAs and miRNAs have been extensively studied, some lncRNA–miRNA interactions remain unclear. The subsequent regulation of cellular signaling pathways in CRC can be treated as potential target to suppress tumor. The negative regulatory function of miR-942 by linc00675 contributes to the inhibition of Wnt/β-catenin signaling and the suppression of the development and progression of CRC[43].

Wnt pathway-related lncRNAs and liver cancer

Wnt/β-catenin signaling, which is the key regulator for the progression of liver tumors, plays a critical role in the development and stemness of cancer cells[50-53]. Diverse oncogenic lncRNAs play important roles in regulating β-catenin by several
Int. J. Biol. Sci. 2018, Vol. 14

mechanisms for the core component of the Wnt/β-catenin signaling pathway (Figure 1). The APC degradation complex and the β-catenin-TCF activating complex are the main targets to regulate β-catenin stability and activation by IncRNAs[53]. For example, IncAPC recruits EZH2 to the APC promoter and inhibits APC transcription, thereby promoting the activation of the Wnt/β-catenin pathway and the self-renewal process of liver tumor initiating cells[54]. LncLAL1A inhibits the formation of APC degradation complex because it recruits CTCF to the axin1 promoter to block Axin1 transcription and activate Wnt/β-catenin signaling pathway[55]. Recent research reported that IncTCF7 can activate TCF7 expression in cis by recruiting the SWI/SNF complex[56]. This evolutionally conserved multi-subunit complex consists of 12–15 subunits with several core components, such as SMARCB1/SNF5, BAF170, and BAF155[57, 58]. After the activation by the SWI/SNF complex, the overexpression of TCF7 combines with the lymphocyte enhancer factor of the transcriptional complex to activate the transcription of downstream genes in Wnt signaling, resulting in the self-renewal of liver cancer stem cells. Moreover, overexpressed linc00210 in liver cancer tissues can bind to CTNNBIP1, thereby impairing CTNNBIP1–β-catenin interaction to promote β-catenin-TCF/LEF interaction and activate Wnt/β-catenin signaling and liver tumor initiating cell self-renewal[59]. Alterations in β-catenin activity directly influence the development of liver tumorigenesis. LncRNA β-Catm, which is associated with β-catenin, enhances the expression of zeste homolog 2 (EZH2) to promote the methylation of β-catenin and inhibit β-catenin ubiquitination[60]. The accumulation of methylated β-catenin allows the activation of Wnt-β-catenin signaling and maintaining the stemness of liver CSCs.

Wnt pathway-related IncRNAs and glioma

Gliomas are the most common and aggressive primary brain tumors and account for approximately 80% of all cases of malignant brain tumors[61, 62]. In the past few years, the interactions of IncRNA and Wnt/β-catenin signaling in glioma have gained increasing research attention. Several IncRNAs, such as AB073614[63], CCAT2[64], CCND2-AS2[65], and DANCER[66], have been identified to be involved in promoting tumor proliferation, migration, and invasion in glioma via the Wnt/β-catenin signal pathway. The AB073614 expression increases in glioma and indicates poor prognosis; scholars have reported that the proliferation and migration of glioma cells can be increased by targeting SOX7 to activate the Wnt/β-catenin signaling pathway[63]. LncRNA CCAT2 is upregulated in glioma tissues, and CCAT2 knockdown inhibits cell proliferation and tumorigenesis potential by suppressing the expression of the downstream genes of the Wnt/β-catenin signaling pathway[64]. LncRNAs, such as CCND2-AS1[65] and DANCER[66], are correlated with poor prognosis in patients with glioma; after Wnt/β-catenin signals are activated, tumor proliferation and invasion are promoted. These finding indicate the involvement of IncRNAs and Wnt/β-catenin signaling pathway in glioma. However, the mechanisms on how IncRNAs activate Wnt/β-catenin signals to promote glioma must be further explored.

Figure 1. Schematic of the activation of Wnt/β-catenin signaling by different oncogenic IncRNAs in liver cancer. Degradation and activating complexes are the two main targets for regulating β-catenin, whereas some IncRNAs may directly regulate β-catenin to influence tumorigenesis.
glioblastoma, and the WNT/β-Catenin pathway involves lncNEAT1 to promote the malignant progression of glioblastoma[71]. Furthermore, knockdown of NEAT1 reduces the trimethylation modification of H3K27 in the presence of the promoters of target-specific genes (Axin2, ICAT, and GSK3B) complex to activate Wnt/β-catenin signaling. In conclusion, as a scaffold, lncRNA NEAT1 could bind to EZH2 and mediate the trimethylation of H3K27 in the presence of the promoters of target-specific genes (Axin2, ICAT, and GSK3B) to promote β-catenin nuclear transport, which might be a novel therapeutic target in glioblastoma.

Wnt pathway-related lncRNAs and GC

GC is the fourth most frequently diagnosed cancer[75] and the second leading cause of cancer-related mortality worldwide[76]. Although lncRNAs play an active role in cancer, their interactions with the WNT/β-catenin pathway are an emerging research field in GC. LncRNA HOTAIR is negatively correlated with miR-34a level; that is, overexpression of HOTAIR decreases the miR-34a level and leads to the activation of the WNT/β-catenin pathway; this phenomenon coincides with increased cellular proliferation[77]. Similarly, lncRNA FEZF1-AS1 and lncRNA LINC01606, whose expression levels are upregulated in GC cells, activate Wnt/β-catenin signaling to promote tumor cell migration and invasion[78, 79]. LncRNA LINC01133 and ENST00000434223 are downregulated in GC tissues and cell lines, and its low expression is positively correlated with EMT and metastasis by inactivating the Wnt/β-catenin pathway[80, 81]. Moreover, lncRNA zinc finger antisense 1 (ZFAS1) has different expression levels in various cancers and exerts anti-tumor or pro-tumor effects on different cancers[82-84] since it was identified in 2011. GC tissue and cell lines highly express ZFAS1, which plays a cancer-promoting role in GC[85, 86]. The underlying mechanism of ZFAS1 in promoting GC may be associated with the Wnt signaling pathway[87]. ZFAS1 recruits numerous transcriptional factors to execute its intracellular biological functions. Enhancer of zeste homolog 2 (EZH2) and LSD1 are two crucial substances that can bind to Kruppel-like factor 2 (KLF2) and NKD2 promoter regions to inhibit their transcription[86]. As a mammalian ortholog of Drosophila naked cuticle, NKD2 has frequent loss of heterozygosity in CRC and GC[88, 89] and negatively regulates canonical Wnt signaling activity by inhibiting dishevelled proteins[90]. Dishevelled proteins disassemble the complex that can destroy β-catenin by phosphorylating LRP5/6; as such, NKD2 can decrease the level of β-catenin in the cytoplasm to inhibit the Wnt signaling pathway. Hence, canonical Wnt signaling is highly activated to promote the malignancies of cancer cells by inhibiting NKD2 through overexpression of ZFAS1 in GC. Furthermore, silencing of ZFAS1 induces the inhibition of cell growth, proliferation, cell cycle, progression, migration, invasion, and EMT and enhances the sensitivity to cis-platinum or paclitaxel by suppressing canonical Wnt signaling[87].

Wnt pathway-related lncRNAs and NSCLC

Lung cancer is one of the most common causes of cancer-associated mortality worldwide[91]. NSCLC accounts for 80%–85%[92] of all cases of lung cancers, leading to big economic losses; the current 5-year survival rate of patients with NSCLC is <15 %[93]. Therefore, clinically useful biomarkers and therapeutic targets should be identified for diagnosis or treatment of NSCLC at an early stage. The upregulation of LINC00968 can promote the growth, migration, and invasion of NSCLC cells upon the activation of the Wnt/β-catenin signaling pathway[94]. Multiple lncRNAs have been identified to contribute to the development and progression of NSCLC via the Wnt/β-catenin signaling pathway. Some examples of lncRNAs are NEAT1[95] and FOXD2-AS1[96], which are also related to Wnt/β-catenin signaling in NSCLC and have been proven as promising tumor gene therapeutic targets because of their abilities to promote the proliferation of NSCLC cells. Increasing the lncRNA SNHG1 expression could also enhance cell proliferation[97]. The expression of SNHG1 has a negative correlation with miR-101-3p, and SOX9 could act as the target of miR-101-3p. Given that SOX9 has a great tendency to control oncogenic Wnt/β-catenin signaling[98-100], SNHG1 promotes NSCLC tumorigenesis and progression via the Wnt/β-catenin pathway through targeting FZD8 in a complex[101]. Furthermore, chemosensitivity is induced through the inactivation of the Wnt/β-catenin pathway. LncRNA Meg3 regulates the specificity of p53 transcriptional activation[102], thereby inhibiting β-catenin/survivin of cancer cells to regulate cisplatin resistance in NSCLC[103].
functions, lncRNAs are deregulated in bladder cancer and play an important role in bladder cancer. The mechanism underlying the interaction between lncRNA and WNT signaling is unclear; however, it is believed that lncRNAs may promote β-catenin expression to induce cisplatin resistance. Hence, the resistance and upregulates UCA1 increased Wnt6 expression to inhibit Dox resistance and upregulate β-catenin expression. Furthermore, lncRNA SNHG1 and UCA1 affect the outcomes of chemotherapy; TUG1 knockdown suppresses β-catenin expression to inhibit Dox resistance and upregulates UCA1 increased Wnt6 expression to induce cisplatin resistance. Hence, the interaction between lncRNA and WNT signaling plays an important role in bladder cancer chemoresistance. In addition to normal physiological functions, lncRNAs are deregulated in bladder cancer development and progression. LncRNA CASC2 is expressed at a low level in bladder cancer and inhibits Wnt/β-catenin signaling by decreasing the expression of β-catenin, thereby suppressing the growth, migration, and invasion of bladder cancer cells[109].

### Conclusion and future perspective

LncRNAs are a highly heterogeneous group of transcripts that regulate gene expression and various aspects of cellular homeostasis, including tumor cell proliferation, survival, and migration or genomic stability through diverse mechanisms[110]. Our collected data confirm that lncRNAs have great roles in the progression of tumorigenesis and, similar to protein-coding genes, are associated with a variety of cell signaling pathways. Although several pathways exist through which lncRNAs may be targeted to modulate biological cellular processes, the Wnt signaling pathway is a common feature of tumors and plays important roles in tumor progression and metastasis of different cancer types[111]. The transcription of lncRNAs can provide signals of malignant transformation through their interactions with other cellular macromolecules, including DNA, protein, and RNA, to activate or suppress the Wnt/β-catenin signaling pathway. Hence, lncRNAs considerably influence the patholog of different cancers. Some Wnt-related lncRNAs that have been associated with cancer but are not reported previously are listed in Table 2. Moreover, the same lncRNAs may have diverse ways to target Wnt/β-catenin signaling in the progression of different carcinomas because of their highly tissue- and cell type-specific...
expression patterns. The interactions between Wnt/β-catenin signaling and IncRNAs have important roles in the development of tumorigenesis. The results provide evidence that IncRNA-Wnt/β-catenin signaling can be a potential target for cancer therapy and a diagnostic indicator to predict responses to treatments.

In summary, Wnt pathway-related IncRNAs are differentially modulated in different types of cancer and the expression of downstream genes is correlated with tumorigenesis, tumor aggressiveness, and stages. The network of IncRNAs and Wnt/β-catenin signaling exhibits potential for discovery of novel diagnostics and therapeutics for cancer. Given that IncRNAs–Wnt pathway increases the therapeutic sensitivity of tumors by modulating several critical genes that confer resistance, the underlying mechanism of such network should be further explored to improve therapeutic efficacy and develop combination therapies. Although a large number of IncRNAs are identified to be associated with Wnt/β-catenin signaling in various types of cancers by binding to miRNAs or by regulating the key factors of Wnt signaling, such as β-catenin and TCF, some Wnt pathway-related IncRNAs and their detailed functions and specificity remain unclear and should be investigated in the future.

Acknowledgments

Funding: This study was funded by grants from the National Natural Science Foundation of China (No. 81472663, 81502280, 81672845 and 81872304), the Education Department of Jiangsu Province (No. 15KJA320006), and the Project of Invigorating Health Care through Science, Technology and Education from Jiangsu Province.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interests

The authors declare that they have no conflict of interest in this study.

References

1. Spizzo R, Almeida M I, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012; 31(43): 4577-87.
2. Shi J, Dong B, Cao J, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget. 2017; 8(16): 27582-92.
3. Dykes I M, Emanuelli C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. Genomics Proteomics Bioinformatics. 2017; 15(3): 177-86.
4. Deniz E, Erman B. Long noncoding RNA (IncRNA), a new paradigm in gene expression control. Funct Integr Genomics. 2017; 17(2-3): 135-43.
5. Brannan C L, Does E C, Ingram R S, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990; 10(1): 28-36.
6. Kwock Z H, Tay Y. Long noncoding RNAs: links between human health and disease. Biochem Soc Trans. 2017; 45(3): 805-12.
7. Li D Y, Busch A, Jin H, et al. H19 Induces Abdominal Aortic Aneurysm Development and Progression. Circulation. 2018; 137(19): e6555.
8. Zhang W, Li Y, Wang P. Long non-coding RNA-ROR aggravates myocardial ischemia/reperfusion injury. Braz J Med Biol Res. 2018; 51(6): e6555.
9. Fan X, Yuan J, Xie J, et al. Long non-protein coding RNA DANCER functions as a competing endogenous RNA to regulate osteosarcoma progression via miR-577/SphK2 axis. Biochem Biophys Res Commun. 2018; 500(3): 658-64.
10. Chen D, Liu L, Wang K, et al. The role of MALAT-1 in the invasion and metastasis of gastric cancer. Scand J Gastroenterol. 2017; 52(6-7): 790-6.
11. Svedova M, SLYSKOVA J, SNIEDEROVA M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014; 35(7): 1510-5.
12. Ma Y, Yang Y, Wang F, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signaling pathway via suppression of activator protein 3. J Cell. 2016; 65(9): 1494-504.
13. Gupta R A, Shah N, Wang K C, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464(7291): 1071-6.
14. Bhan A, Soleimani M, Mandal S S. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15): 3965-81.
15. Wang K C, Chang H Y. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6): 904-14.
16. Sun L, Jiang C, Xu C, et al. Down-regulation of long non-coding RNA RP1-1-790H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway. Oncotarget. 2017; 8(17): 27299-302.
17. Yu T, Zhao Y, Hui Z, et al. MetaLnc9 Facilitates Lung Cancer Metastasis via a PKG1-Activated AKT/mTOR Pathway. Cancer Res. 2017; 77(21): 5792-94.
18. Crea F, Clermont P L, Parola A, et al. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 2014; 33(1): 1-16.
19. Nusse R, Varmus H E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982; 31(1): 99-109.
20. Peng Y, Zhang X, Feng X, et al. The crosstalk between microRNAs and the Wnt/beta-catenin signaling pathway in cancer. Oncotarget. 2017; 8(8): 14089-106.
21. Nusse R, Clevers H. Wnt/beta-catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017; 169(6): 985-99.
22. Liu C, Kato Y, Zhang Z, et al. beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A. 1999; 96(11): 6275-8.
23. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J. 2012; 31(12): 2714-36.
24. Rao T P, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010; 106(12): 1798-806.
25. Anastas J N, Moon R T. WNT signaling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13(13): 11-26.
26. Derksen P W, Tjin E, Meijer H P, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004; 101(16): 6122-7.
27. Yeung J, Esposito M T, Gandillet A, et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010; 18(6): 606-18.
28. Yook J, Li J Y, Ota I, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail activity in breast cancer cells. Nat Cell Biol. 2006; 8(12): 1398-406.
29. Xie Y, Tang B, Xiao Y, et al. Long non-coding RNAs in colorectal cancer. Oncotarget. 2016; 7(5): 5226-39.
30. Xiao Z, Qu Z, Chen Z, et al. IncRNA HOTAIR is a Prognostic Biomarker for the Proliferation and Chemoresistance of Colorectal Cancer via MiR-203a-3p-Mediated Wnt/s-Serine Pathway. Pathway. Cell Physiol Biochem. 2018; 46(3): 1275-85.
31. Lu Y, Zhao X, Liu Q, et al. IncRNA MIR100HG-derived mir-100 and mir-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. Nat Med. 2017; 23(11): 1331-41.
32. Bafico A, Liu G, Yaniv A, et al. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP4/6. Arrow. Nat Cell Biol. 2001; 3(7): 683-6.
33. Nakamura R E, Hackam S A. Analysis of Dickkopf3 interactions with Wnt signalling receptors. Growth Factors. 2010; 28(4): 232-42.
34. de Lau W, Feng C, Gross P, et al. The R-spondin/Lgr5/Erb43 module: regulator of Wnt signal strength. Genes Dev. 2014; 28(4): 305-16.
35. Jiang X, Charlat O, Zapponi R, et al. Disheveled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol Cell. 2015; 58(3): 522-33.
36. Cruciat C M, Niehrs C. Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013; 5(3): a015081.
37. MacDonald B T, Tamao K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1): 1-11.
38. Sun N, Zhang G, Liu Y, et al. Overexpressing RNAi XIST sponges miR-34a to promote colon cancer progression via Wnt/beta-catenin signaling pathway. Gene. 2018;
39. Zhang Z, Zhou C, Chang Y, et al. Long non-coding RNA CASC11 interacts with hnRNPK and activates the WNT/beta-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett. 2016; 378(1): 62-73.
40. Li Y, Zhu J, et al. Long non-coding RNA IncTC7 activates the Wnt/beta-catenin pathway to promote metastasis and invasion in colorectal cancer. Oncol Lett. 2017; 14(6): 7840-90.
41. Lin J, Tan X, Qiu L, et al. Long Noncoding RNA BC029913 as a Novel Therapeutic Target for Colorectal Cancer That Suppresses Metastasis by Upregulating TIMP3. Mol Ther Nucleic Acids. 2017; 8:469-81.
42. Wang G, Li Z, Zhao Q, et al. IncRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway. Oncol Rep. 2014; 31(4): 1839-45.
43. Shan Z, An N, Qin J, et al. Long non-coding RNA Lin00876 suppresses cell proliferation and metastasis in colorectal cancer via acting on miR-942 and Wnt/beta-catenin signaling. Biomed Pharmacother. 2018; 101:769-76.
44. Ouyang S, Zheng X, Zhou X, et al. IncRNA BCAR4 promotes colon cancer proliferation by activating Wnt/beta-catenin signaling. Oncotarget. 2017; 8(54): 92815-60.
45. Liu X B, Han C, Sun C Z. Long non-coding RNA DLEU2-AS1 promotes the occurrence and development of colorectal cancer via Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci. 2018; 22(1): 110-7.
46. Zhang X, Xiong Y, Tang F, et al. Long noncoding RNA HNFA1-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of Wnt/beta-catenin signaling pathway. Biomed Pharmacother. 2017; 96:877-83.
47. Wu K F, Liang W C, Feng L, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/beta-catenin pathway. Exp Cell Res. 2017; 359(2): 282-7.
48. Qin L, Yang J, Wang F, et al. Long non-coding RNA SNHG1 promotes cell proliferation and tumorigenesis in colorectal cancer via Wnt/beta-catenin signaling. Pharmacol. 2017; 72(5): 395-401.
49. Yuan Z, Yu X, Ni B, et al. Overexpression of long non-coding RNA-CTD903 inhibits colorectal cancer invasion and migration by repressing Wnt/beta-catenin signaling and predicts favorable prognosis. Int J Onco. 2016; 48(6): 2675-85.
50. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(7): 469-80.
51. Hofmeyer K, Raggioli A, Rudloff S, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012; 336(6088): 1549-54.
52. Liu L, Su N, Boersma P J, et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell. 2012; 149(6): 1245-56.
53. Deschene E R, Myung P, Rompolas P, et al. Beta-Catenin activation regulates tissue growth non-cell autonomously in the hair stem cell niche. Science. 2014; 343(6177): 1353-9.
54. Fu X, Lin J, Qin F, et al. LncAPC drives Wnt/beta-catenin activation and liver tissue growth through regulating miR-942-3p. Mol Cancer. 2018; 17(3): 408-18.
55. Xu D, Yang F, Yuan J H, et al. Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/beta-catenin signaling. Hepatol. 2015; 52(2): 739-51.
56. Wang Y, He J, Liu Y, et al. The long noncoding IncTC7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling, Cell Stem Cell. 2015; 16(4): 413-25.
57. Zhang X, Xiong Y, Qin F, et al. LncAPC drives Wnt/beta-catenin activation and liver tumor invasion and metastasis through CTNNBIP1-dependent manner. Mol Cancer. 2018; 17(1): 73.
58. Zhu P, Wang Y, Huang G, et al. Inc-beta-CATm elicits EZH2-mediated APC transcriptional inhibition. Mol Cancer. 2018; 17(3): 408-18.
59. Wu X, He L, Fu M, et al. Snord-host RNA Zfas1 is involved in the formation of epithelial-mesenchymal transition in colorectal cancer. Int J Biochem Cell Bio. 2018; 103:125-34.
60. Yang X Z, Cheng T T, He Q J, et al. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/beta-catenin pathway. Mol Cancer. 2018; 17(1): 126.
61. Zhao Y X, Liu J F, Sun W H, et al. Long non-coding RNA ENST00000434223 suppresses tumor progression in gastric cancer cells through activating Wnt/beta-catenin signaling pathway. Biomed Pharmacother. 2017; 96:1103-8.
62. Luo Y, Tan W, Jia W, et al. The long non-coding RNA LINC01660 contributes to the metastasis and invasion of human gastric cancer and is associated with Wnt/beta-catenin signaling. Int J Biochem Cell Bio. 2018; 103:93-15.
63. Siegel R L, Miller K D, Fedewa S A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3): 175-93.
64. Araneta M J, Xu M, et al. SNORD-host RNA Zfas1 is a novel Wnt/beta-catenin-interacting protein. Genes Dev. 2000; 14(14): 1741-9.
65. Dominguez M J, Rambow F, Job B, et al. Wnt/beta-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res. 2014; 74(7): 1983-95.
66. Askarian-Amiri M E, Crawford J, French J D, et al. SNORD-host RNA Zfas1 is a novel Wnt/beta-catenin-interacting protein. Genes Dev. 2000; 14(14): 1741-9.
67. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(7): 469-80.
68. Ong M S, Cai W, Yuan Y, et al. ‘Lnc’-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signaling. Br J Pharmacol. 2017; 174(24): 4648-70.
69. Choudhry H, Albubhairi A, Morotti M, et al. Tumor hyposxia triggers nuclear parapscle formation through HIF-2alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene. 2015; 34(34): 4446-56.
70. Wu Y, Yang L, Zhao J, et al. Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer. Mol Cell. 2015; 14:191.
71. Baek S,  Slingerland  J M, et al. The eotaxin receptor alpha-regulated IncRNA NEAT1 is a critical mediator of prostate cancer. Nat Commun. 2014; 5:5383.
72. Chen Q, Cai J, Wang Q, et al. Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/beta-Catenin Pathway by Scaffolding EZH2. Clin Cancer Res. 2018; 24(3): 684-95.
73. Xu J H, Zhang T, Domon C, et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell. 2002; 9(2): 1172-83.
74. Tago K, Nakamura T, Nishita M, et al. Inhibition of Wnt signaling by ICAT, a novel Wnt/beta-catenin-interacting protein. Genes Dev. 2000; 14(14): 1741-9.
75. Dominguez M J, Rambow F, Job B, et al. Wnt/beta-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res. 2014; 74(7): 1983-95.
96. Rong L, Zhao R, Lu J. Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2017; 484(1): 586-91.

97. Cui Y, Zhang F, Zhu C, et al. Upregulated IncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. Oncotarget. 2017; 8(11): 17853-94.

98. Santos J C, Carrasco-Garcia E, Garcia-Puga M, et al. SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Cancer Res. 2016; 76(22): 6735-46.

99. Ma F, Ye H, He H H, et al. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016; 126(9): 3745-56.

100. Prevostel C, Rammah-Bouazza C, Trauchessec H, et al. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/β-catenin signaling. Oncotarget. 2016; 7(50): 82228-43.

101. Fu X, Li H, Liu C, et al. Long noncoding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/beta-catenin signaling pathway. Oncotarget Ther. 2016; 9:3815-27.

102. Zuo C, Zhong W, Yang Y, et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007; 282(24): 24731-42.

103. Xia Y, He Z, Liu B, et al. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway. Mol Med Rep. 2015; 12(3): 4530-7.

104. Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87-108.

105. Chou R, Selph S S, Buckley D I, et al. Treatment of muscle-invasive bladder cancer via Wnt/beta-catenin pathway. Biochem Biophys Res Commun. 2017; 484(3): 586-91.

106. Jiang Z, Jiang C, Fang J. Up-regulated lnc-SNHG1 contributes to osteosarcoma progression through sequestration of miR-577 and activation of WNT2B/Wnt/beta-catenin pathway. Biochem Biophys Res Commun. 2018; 495(1): 238-45.

107. He S, Zhao Y, Wang X, et al. Up-regulation of long non-coding RNA SNHG20 promotes ovarian cancer progression via Wnt/beta-catenin signaling. Biosci Rep. 2018; 38(1): BSRR20170681.

108. Tian Z, Yang G, Jiang P, et al. Long non-coding RNA Sox4 promotes proliferation and migration by activating Wnt/beta-catenin signaling pathway in osteosarcoma. Pharmacazie. 2017; 72(9): 537-42.

109. Yang Y T, Wang Y F, Lai J Y, et al. Long non-coding RNA UCA1 contributes to the progression of oral squamous cell carcinoma by regulating the WNT/beta-catenin signaling pathway. Cancer Sci. 2016; 107(11): 1581-9.

110. Pei Z, Du X, Song Y, et al. Down-regulation of lncRNA CASC2 promotes cell growth by regulating the Wnt signaling pathway. Oncotarget. 2015; 68059-70.

111. Shi H, Cui Y, Zhang F, et al. Highly expressed long non-coding RNA FOXD2-AS1 leads to chemoresistance of breast cancer cells by suppressing the Wnt/beta-catenin signaling pathway. BMC Neuro. 2017; 17(1): 30.

112. Jiang Y, Chen Q, Wang Y, et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012; 8(9): 2289-94.

113. Yuan P, Zhang H, Hu X, et al. Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/beta-catenin pathway. Oncotarget. 2017; 8(51): 88689-96.

114. Fan Y, Shen B, Tan M, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014; 281(7): 1750-8.

115. Pei Z, Du L, Song Y, et al. Down-regulation of IncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/beta-catenin signaling pathway. Oncotarget. 2017; 8(11): 18145-53.

116. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015; 21(11): 1253-61.

117. Shi H, Cui Y, Zhang F, et al. Highly expressed long non-coding RNA FOXD2-AS1 leads to chemoresistance of breast cancer cells by suppressing the Wnt/beta-catenin signaling pathway. J Clin Invest. 2016; 126(5): 1745-58.